Scailyte

📍 Basel, Switzerland🗓 Founded 2017👥 27 employees💰 Last funded Dec 2018
Biotechnology🌐 scailyte.com
Website LinkedIn
True precision medicine through single-cell science. Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human's hidden "single-cell"​ secrets. The performance and clinically-relevant application of Scailyte's platform ScaiVision have been demonstrated in numerous clinical projects that resulted in patent-pending biomarkers. Scailyte has a growing pipeline of clinical projects in immunology, oncology and women's health supported by top clinicians and access to high quality proprietary datasets. If you want to partner with us and save lives by enabling precision medicine, reach out to contact@scailyte.com More information about our company, technology & services you can find on our website - https://scailyte.com
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
2
Frequently asked questions
Who invested in Scailyte?
Scailyte has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Scailyte last raise funding?
The most recent investment in Scailyte recorded on gritt.io was in December 2018.
When was Scailyte founded?
Scailyte was founded in 2017.
What industry is Scailyte in?
Scailyte operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Scailyte based?
Scailyte is headquartered in Basel, Switzerland.